Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Roche is acquiring Poseida Therapeutics for $1.5 billion to enhance its pipeline with CAR-T cell therapies.

Portfolio Pulse from

November 26, 2024 | 5:15 pm

Roche's phase III trial for a combination of tiragolumab and tecentriq in treating lung cancer did not meet its desired outcomes, marking a setback for the company.

Portfolio Pulse from

November 26, 2024 | 7:00 am

Roche is set to acquire Poseida Therapeutics, a California-based biopharma company, for $9 per share, totaling an equity value of $1 billion.

Portfolio Pulse from

November 26, 2024 | 6:45 am

Poseida Therapeutics, Inc. is set to be acquired by Roche Holdings, Inc. for up to $13.00 per share, including a $9.00 cash payment at closing and a contingent value right (CVR) for up to $4.00 per share. The acquisition values Poseida at approximately $1.5 billion.

Portfolio Pulse from

November 26, 2024 | 6:30 am

Genentech, part of the Roche Group, has provided an update on its Phase III SKYSCRAPER-01 study. This study evaluates the combination of tiragolumab and Tecentriq against Tecentriq alone for treating PD-L1-high, locally advanced or metastatic non-small cell lung cancer.

Portfolio Pulse from

November 26, 2024 | 6:15 am

Roche has received FDA approval for the PATHWAY HER2 (4B5) test, a companion diagnostic to identify patients with HER2-positive biliary tract cancer eligible for treatment with ZIIHERA. This approval provides a new option for BTC patients, who often have limited treatment choices.

Portfolio Pulse from

November 25, 2024 | 6:15 am

Neuron23 is utilizing Roche's digital biomarker in its Phase 2 NEULARK trial for NEU-411, targeting early Parkinson's disease.

Portfolio Pulse from

November 19, 2024 | 12:45 pm

Flare Therapeutics has entered a strategic collaboration with Roche to discover novel small molecules targeting transcription factors in oncology. Flare will receive $70 million upfront, with potential milestone payments exceeding $1.8 billion, plus royalties.

Portfolio Pulse from

November 12, 2024 | 12:15 pm

The article compares Roche Holding AG (RHHBY) and AbbVie (ABBV) to determine which is a better value stock in the Large Cap Pharmaceuticals sector.

Portfolio Pulse from

November 07, 2024 | 6:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.